NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama)

Active Not RecruitingPhase 3

Sponsor: Definium Therapeutics US, Inc.

Conditions: Generalized Anxiety Disorder

Interventions: Placebo, DT120

Countries: United States, Czechia, France, Germany, Poland, United Kingdom

A Phase 3, Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating DT120 Compared to Placebo in Generalized Anxiety Disorder - Panorama

Eligibility overview

Sex: ALL

Age: 18 Years to 74 Years

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

1. Diagnosis of GAD per DSM-5
2. Male or female aged 18 to 74
3. HAM-A Total Score ≥20

Exclusion Criteria:

1. Certain psychiatric disorders (other than generalized anxiety disorder)
2. First degree relative with or lifetime history of a psychotic disorder or bipolar disorder
3. Current diagnosis of alcohol or substance use disorder (excluding nicotine and caffeine)
4. Any clinically significant unstable illness

Locations (36)

Little Rock, Arkansas, United States
Los Angeles, California, United States
Los Angeles, California, United States
Bradenton, Florida, United States
Orlando, Florida, United States
Atlanta, Georgia, United States
Towson, Maryland, United States
Boston, Massachusetts, United States
Princeton, New Jersey, United States
Cincinnati, Ohio, United States
North Canton, Ohio, United States
Austin, Texas, United States
Everett, Washington, United States
Pilsen, Czechia
Prague, Czechia
Prague, Czechia
Douai, France
Marseille, France
Paris, France
Paris, France
Sotteville-lès-Rouen, France
Berlin, Germany
Berlin, Germany
Mannheim, Germany
Tübingen, Germany
Gdansk, Poland
Gdansk, Poland
Lodz, Poland
Glasgow, United Kingdom
Gosforth, United Kingdom
+ 6 more on CT.gov